低剂量IL-2治疗难治性系统性红斑狼疮:一项研究者发起的单中心1期和2a期临床试验
该单中心非对照1/2a期试验评估低剂量重组人IL-2(阿地白介素)治疗中重度活动性系统性红斑狼疮的安全性和对调节性T细胞的影响。12例患者中11例(92%)达到主要终点,多数治疗相关不良事件为轻中度,未发生严重不良事件,且83%患者第62天SELENA-SLEDAI评分下降。
要点
- 低剂量IL-2安全耐受,最常见不良事件为注射部位反应(20%)。
- 92%患者第62天调节性T细胞中CD25hi表达细胞比例增加至少100%。
- 83%患者第62天SELENA-SLEDAI评分较基线下降,未观察严重疾病 flare。
核心结论
- 低剂量IL-2治疗在中重度系统性红斑狼疮患者中安全且耐受良好,并选择性促进功能性调节性T细胞扩增。
- 低剂量IL-2可能有助于降低疾病活动度,但需更大规模试验验证疗效。
研究设计与样本
- 研究者发起的单中心、非对照1期和2a期临床试验,在德国柏林Charité大学医学院风湿病与临床免疫科进行。
- 纳入10例18-75岁确诊系统性红斑狼疮且既往至少两种常规治疗下仍为中重度活动的患者,另2例在同情用药条件下治疗,共12例。
- 治疗方案为四个周期低剂量阿地白介素每日给药5天,随后休息9-16天。
主要发现
- 12例患者中11例(92%)达到主要终点,即第62天循环CD3+CD4+FOXP3+CD127lo调节性T细胞中CD25hi表达细胞比例增加至少100%。
- 共记录159例不良事件,其中75例(47%)与治疗相关,大多数为短暂轻中度(1-2级),最常见为注射部位反应(20%),治疗期间无严重不良事件。
- 12例患者中10例(83%)第62天SELENA-SLEDAI评分低于基线,治疗期间未观察到严重疾病 flare。
- 疾病活动度下降与活化调节性T细胞比例增加幅度相关,IL-2治疗优先促进保留抑制功能的调节性T细胞增殖,并观察到参与生发中心反应调节的细胞减少。
关键数值与推荐
- 主要终点为安全性和第62天(即四个治疗周期后)循环CD3+CD4+FOXP3+CD127lo调节性T细胞中CD25hi表达细胞比例增加至少100%的患者数。
- 次要终点包括第62天通过SELENA-SLEDAI和BILAG评分评估的疾病活动度、通过SLEDAI flare指数评估的疾病 flare、自身抗体和补体浓度。
临床怎么用
- 低剂量IL-2可能作为中重度系统性红斑狼疮患者的选择之一,但当前证据来自非对照小样本试验,需更大规模对照研究确认疗效。
- 治疗期间应监测注射部位反应等不良事件,并评估调节性T细胞比例及疾病活动度变化。
局限性
- 非对照、单中心、小样本设计(共12例,其中2例为同情用药),疗效结论需更大规模试验验证。
- 原文未报告盲法、随机化及长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An acquired deficiency of interleukin-2 (IL-2) and related defects in regulatory T cell homeostasis are thought to play a crucial role in the pathogenesis of systemic lupus erythematosus. We hypothesised that reconstitution of regulatory T-cell homoeostasis with low doses of IL-2 would be beneficial to patients with systemic lupus erythematosus. METHODS: In this uncontrolled, phase 1 and 2a trial done in the Department of Rheumatology and Clinical Immunology at Charité-University Medicine Berlin (Berlin, Germany), we assessed the safety and tolerability of low-dose recombinant human IL-2 (aldesleukin) and its effects on regulatory T cells. We recruited patients aged 18-75 years with a confirmed diagnosis of systemic lupus erythematosus and moderate-to-severe disease activity despite previous treatment with at least two conventional therapies. Patients were given four cycles of low-dose aldesleukin daily for 5 days followed by a 9-16 day rest. The primary endpoints were safety and the number of patients who achieved at least a 100% increase in the proportion of CD25hi-expressing cells among circulating CD3 + CD4 + FOXP3 + CD127lo regulatory T cells at day 62 (ie, after four treatment cycles). Secondary endpoints included disease activity as measured by the Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG) score, disease flares as measured by the SLEDAI flare index, auto-antibody and complement concentrations at day 62. Exploratory endpoints included various cellular and immunological parameters. The trial is registered with WHO/ICTRP, number DRKS00004858. FINDINGS: Between March 31, 2014, and May 27, 2016, 13 patients were screened, of whom ten met eligibility criteria and were enrolled in the trial. Two additional patients were treated between April 1, 2013, and March 11, 2014, in a compassionate use setting. Eleven (92%) of the 12 patients achieved the primary endpoint. 159 adverse events were recorded, 75 (47%) of which were treatment related. Most treatment-related adverse events were transient and mild to moderate (grade 1-2). The most common adverse event was injection-site reaction (20%). No serious adverse events occurred during the treatment period. In ten (83%) of 12 patients, SELENA-SLEDAI scores were lower at day 62 than at baseline, and no severe disease flares were observed during the treatment period. Decreased disease activity correlated with the magnitude of increase in the proportion of activated regulatory T cells. IL-2 treatment resulted in a preferential proliferation of regulatory T cells that retained suppressive capacity. We observed decreases in cells that are involved in the regulation of germinal-centre reactions. INTERPRETATION: Low-dose IL-2 therapy is safe and well tolerated and selectively promotes the expansion of functional regulatory T cells in patients with moderate-to-severe systemic lupus erythematosus. Low-dose IL-2 treatment might also be beneficial in reducing disease activity, although larger trials are needed to address efficacy. FUNDING: German Research Foundation.
引用
- Humrich JY, von Spee-Mayer C, Siegert E, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019. PMID: 38229359. doi:10.1016/S2665-9913(19)30018-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。